HISTORY
2025
06 | Certified as an Excellent Company for Employee Invention Compensation |
05 | Selected for the Next Challenge Global Collaboration Program with Astellas |
04 | Chosen as a joint research partner for the Ministry of Health and Welfare’s Genome Editing-Based Therapeutics Development Program |
2024
12 | Innobiz company certification completed |
11 | Adeno-associated virus mutant patent application |
10 | Patent registration for high-yield, high-quality recombinant adeno-associated virus production method |
08 | Selection of Global Industrial Technology Cooperation Center project (joint research institute) |
08 | Selection of 2024 Seoul-type R&D biomedical technology commercialization support project |
07 | Patent application for BEST1 gene editing method using CRISPR/Cas system |
05 | Selection of baby unicorn fostering project |
05 | Selection of scale-up tips project |
2023
10 | Series A 5 billion won investment attraction completed (TS Investment, Shinhan Capital, Smilegate Investment, Wonik Investment Partners) |
4 | Selected as one of 100 startups in materials, parts, and equipment |
2022
12 | Completed application for provisional specification of Korean patent for recombinant AAV manufacturing method |
09 | Expansion of business location (Addition of 1021 and 1022, B-dong 2, Hanam Hyundai Knowledge Industry Center Hangang Misa) |
08 | A total of 8 government projects and support projects selected (Cumulative government and local government support project cost of approximately 6.5 billion won), Recruitment of first research institute director and strategic planning headquarters director |
07 | Selection of Gyeonggi-do type smart factory construction support project |
07 | Ministry of Health and Welfare regenerative medicine clinical research infrastructure establishment project cell gene therapy Project selected for development of virus materials and production technology for production |
2021
12 | Selected for TIPS Startup Commercialization Project (Public-Private Joint Entrepreneur Discovery and Incubation Project), Selected for Seoul Biohub Entry Permit Company (BT-IT Convergence Center) and Completed Installation of Seoul Branch |
11 | Venture business certification completed, corporate research institute LMO & Biosafety Level 2 approval completed |
10 | Konkuk University School of Medicine and Rare and Incurable Disease Pipeline MOU signed for joint research |
08 | Business location Hanam Hyundai Knowledge Industry Center Moved into 1023 (headquarters), 1014 (laboratory) of B-dong 2, Hangang Misa(including relocation of corporate research institute) |
07 | 2 papers published, technology transfer agreement with Kyungpook National University, Selected as a project for TIPS R&D Startup Growth Technology Development Project |
05 | Innopolis Partners (Ltd.) Attracts seed investment (headquarters), Establishes corporate research institute |
2020
09 | Establishment of Aavatar Therapeutics Inc. |
Innovation in gene therapy, changing the lives of patients with rare and incurable diseases.
We are with you through the entire process of rare disease treatment, from the development of AAV platform technology to the production of customized treatments.
COMPANY | AAVATAR Therapeutics
CEO | Seunghee Cho
BUSINESS NUMBER | 235-81-02296
HQ
Unit 1023, Building B, 540 Misa-daero,
Hanam-si, Gyeonggi-do, Republic of Korea
BioHub
Room 203, R&D Center, Seoul Bio Hub, 117-3,
Hoegi-ro, Dongdaemun-gu, Seoul, Republic of Korea
Copyright ⓒ 2025 AAVATAR Therapeutics All rights reserved.
Innovation in gene therapy, changing the lives of patients with rare and incurable diseases.
We are with you through the entire process of rare disease treatment, from the development of AAV platform technology to the production of customized treatments.
MON — FRI (8 AM ~ 5 PM)
TEL | 070-4229-0321
EMAIL | information@aavatartps.com
Customer Center
070-4229-0321
MON~FRI 8:00 ~ 17:00
COMPANY | AAVATAR Therapeutics CEO | Seunghee Cho BUSINESS NUMBER | 235-81-02296
HQ | Unit 1023, Building B, 540 Misa-daero, Hanam-si, Gyeonggi-do, Republic of Korea
BioHub | Room 203, R&D Center, Seoul Bio Hub, 117-3, Hoegi-ro, Dongdaemun-gu, Seoul, Republic of Korea
Copyright ⓒ 2025 AAVATAR Therapeutics All rights reserved. | SITE BY. DOTCLE